Author

Jim Ford

Institution: Merus (Netherlands)

Observed institution: Merus (Netherlands)

OpenAlex ID: A5002467795

Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer

2025 · Alison M. Schram, Koichi Goto, et al. · New England Journal of Medicine · 140

Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.

2022 · Alison M. Schram, Koichi Goto, et al. · Journal of Clinical Oncology · 65

Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.

2021 · Alison M. Schram, Eileen Mary O'Reilly, et al. · Journal of Clinical Oncology · 54

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions

2024 · Dong-Wan Kim, Alison M Schram, et al. · Future Oncology · 43

Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).

2020 · Barbara Pistilli, Hans Wildiers, et al. · Journal of Clinical Oncology · 34

Abstract PR02: Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers

2019 · Alison M Schram, Eileen M O’Reilly, et al. · Molecular Cancer Therapeutics · 28

LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC

2025 · Jean-Pascal Machiels, Jérôme Fayette, et al. · Future Oncology · 14

Results: other solid tumours (excluding non-small cell lung cancer)

2013 · Jim Ford, E Cummins, et al.

Results: non-small cell lung cancer

2013 · Jim Ford, E Cummins, et al.

Results: other solid tumours (including non-small cell lung cancer)

2013 · Jim Ford, E Cummins, et al.

Works count: 10

Citation count: 378

H-index: 7

I10-index: 7